Cargando…

Correction: Fluvastatin Interferes with Hepatitis C Virus Replication via Microtubule Bundling and a Doublecortin-like Kinase-Mediated Mechanism

Detalles Bibliográficos
Autores principales:	Ali, Naushad, Allam, Heba, Bader, Ted, May, Randal, Basalingappa, Kanthesh M., Berry, William L., Chandrakesan, Parthasarathy, Qu, Dongfeng, Weygant, Nathaniel, Bronze, Michael S., Umar, Shahid, Janknecht, Ralf, Sureban, Sripathi M., Huycke, Mark, Houchen, Courtney W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3865335/ http://dx.doi.org/10.1371/annotation/fcc840e2-225c-4d71-920d-a1eab7747e19

Ejemplares similares

Fluvastatin Interferes with Hepatitis C Virus Replication via Microtubule Bundling and a Doublecortin-like Kinase-Mediated Mechanism
por: Ali, Naushad, et al.
Publicado: (2013)

Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1
por: Weygant, Nathaniel, et al.
Publicado: (2014)

Ablation of Doublecortin-Like Kinase 1 in the Colonic Epithelium Exacerbates Dextran Sulfate Sodium-Induced Colitis
por: Qu, Dongfeng, et al.
Publicado: (2015)

Inflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseases
por: Ali, Naushad, et al.
Publicado: (2015)

Intestinal tuft cells regulate the ATM mediated DNA Damage response via Dclk1 dependent mechanism for crypt restitution following radiation injury
por: Chandrakesan, Parthasarathy, et al.
Publicado: (2016)

Dclk1 facilitates intestinal tumor growth via enhancing pluripotency and epithelial mesenchymal transition
por: Chandrakesan, Parthasarathy, et al.
Publicado: (2014)

Doublecortin-like kinase 1 promotes hepatocyte clonogenicity and oncogenic programming via non-canonical β-catenin-dependent mechanism
por: Ali, Naushad, et al.
Publicado: (2020)

Dietary Pectin Increases Intestinal Crypt Stem Cell Survival following Radiation Injury
por: Sureban, Sripathi M., et al.
Publicado: (2015)

Dclk1(+) small intestinal epithelial tuft cells display the hallmarks of quiescence and self-renewal
por: Chandrakesan, Parthasarathy, et al.
Publicado: (2015)

Doublecortin-Like Kinase 1 Is Elevated Serologically in Pancreatic Ductal Adenocarcinoma and Widely Expressed on Circulating Tumor Cells
por: Qu, Dongfeng, et al.
Publicado: (2015)

Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism
por: Sureban, Sripathi M., et al.
Publicado: (2015)

Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells
por: Chandrakesan, Parthasarathy, et al.
Publicado: (2017)

DCLK1 Regulates Pluripotency and Angiogenic Factors via microRNA-Dependent Mechanisms in Pancreatic Cancer
por: Sureban, Sripathi M., et al.
Publicado: (2013)

Elevated doublecortin-like kinase 1 serum levels revert to baseline after therapy in early stage esophageal adenocarcinoma
por: Christman, Emily M., et al.
Publicado: (2019)

Tuft and Cancer Stem Cell Marker DCLK1: A New Target to Enhance Anti-Tumor Immunity in the Tumor Microenvironment
por: Cao, Zhiyun, et al.
Publicado: (2020)

DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma
por: Weygant, Nathaniel, et al.
Publicado: (2014)

Regulatory Roles of Dclk1 in Epithelial Mesenchymal Transition and Cancer Stem Cells
por: Chandrakesan, P, et al.
Publicado: (2016)

DCLK1 Regulates Tumor Stemness and Cisplatin Resistance in Non-small Cell Lung Cancer via ABCD-Member-4
por: Panneerselvam, Janani, et al.
Publicado: (2020)

Targeting Doublecortin-Like Kinase 1 (DCLK1)-Regulated SARS-CoV-2 Pathogenesis in COVID-19
por: Undi, Ram Babu, et al.
Publicado: (2022)

Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism
por: Sureban, Sripathi M, et al.
Publicado: (2011)

Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer
por: Qu, Dongfeng, et al.
Publicado: (2019)

DCLK1 Monoclonal Antibody-Based CAR-T Cells as a Novel Treatment Strategy against Human Colorectal Cancers
por: Sureban, Sripathi M., et al.
Publicado: (2019)

Glycine encephalopathy
por: Bhumika, S., et al.
Publicado: (2022)

Epigenetic Landscape and Therapeutic Implication of Gene Isoforms of Doublecortin-Like Kinase 1 for Cancer Stem Cells
por: Moore, Landon L., et al.
Publicado: (2023)

Enantiospecific Pharmacogenomics of Fluvastatin
por: Hirvensalo, Päivi, et al.
Publicado: (2019)

Cancer Stem Cell Marker DCLK1 Correlates with Tumorigenic Immune Infiltrates in the Colon and Gastric Adenocarcinoma Microenvironments
por: Wu, Xiangyan, et al.
Publicado: (2020)

Bufalin Inhibits Tumorigenesis, Stemness, and Epithelial–Mesenchymal Transition in Colorectal Cancer through a C-Kit/Slug Signaling Axis
por: Ding, Ling, et al.
Publicado: (2022)

The evolving doublecortin (DCX) superfamily
por: Reiner, Orly, et al.
Publicado: (2006)

Doublecortin Mutation in an Adolescent Male
por: Zare, Isabelle, et al.
Publicado: (2019)

The Difference in Pharmacokinetics and Pharmacodynamics between Extended-Release Fluvastatin and Immediate-Release Fluvastatin in Healthy Chinese Subjects
por: Xu, H. R., et al.
Publicado: (2012)

Journal of Basic and Clinical Pharmacy signs collaboration agreement with Medknow Publications-Wolters Kluwer Health
por: Harsha, Sree, et al.
Publicado: (2012)

Effect of taxol from Pestalotiopsis mangiferae on A549 cells-In vitro study
por: Kathiravan, Govindarajan, et al.
Publicado: (2009)

Editorial: Novel immunotherapies to treat gastrointestinal solid tumor cancers
por: Sureban, Sripathi M., et al.
Publicado: (2022)

Effects of Fluvastatin on the Pharmacokinetics of Repaglinide: Possible Role of CYP3A4 and P-glycoprotein Inhibition by Fluvastatin
por: Lee, Chong-Ki, et al.
Publicado: (2013)

A word from Journal of Basic and Clinical Pharmacy editor's desk
por: Sureban, Sripathi M., et al.
Publicado: (2012)

Inflammatory Mediators and Gut Microbial Toxins Drive Colon Tumorigenesis by IL-23 Dependent Mechanism
por: Panneerselvam, Janani, et al.
Publicado: (2021)

Kinetic Spectrophotometric Determination of Fluvastatin in Pharmaceutical Preparations
por: Ashour, Safwan, et al.
Publicado: (2010)

Immunohistochemical study of doublecortin and nucleostemin in canine brain
por: De Nevi, E., et al.
Publicado: (2013)

Could Nutraceutical Approaches Possibly Attenuate the Cytokine Storm in COVID-19 Patients?
por: Vignesh, Ramachandran, et al.
Publicado: (2021)

Inhibition of Candida albicans by Fluvastatin Is Dependent on pH
por: Schmidt, Martin, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_jru5qsdu2453sk9r35r0a464ea